Filing Flows › Krystal Biotech (KRYS) › Q2 2026
Krystal Biotech (KRYS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Krystal Biotech (KRYS) reported revenue of $119M for the second quarter 2026 (Q2 2026), +24% from a year earlier and +2% from the quarter before. Operating margin was 49.0%, net earnings $54.8M (45.9% of revenue).
Krystal Biotech, Q2 2026: revenue $119M (+24% year over year), operating margin 49.0%, net earnings $54.8M, operating cash flow $74.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $119M | +2% | +24% |
| Operating profit | $58.4M | +9% | +48% |
| Net earnings | $54.8M | -2% | +43% |
| Operating cash flow | $74.8M | -7% | +42% |
| Free cash flow | $71.2M | -3% | +40% |
What changed
Revenue was $119.2M in Q2 2026, up 24% year over year and up 2% from the previous quarter.
Operating profit was $58.4M, a 49.0% margin (up 8.0 points year over year). Of the extra revenue versus Q2 2025, 82% reached operating profit, above the 41% margin then. Total costs grew 7% against revenue growth of 24%. The fastest-growing cost line was SG&A (+14%). Net earnings were $54.8M, up 43% year over year. The effective tax rate was 17.1%.
Operating cash flow was $74.8M (up 42% year over year), 137% of net earnings. Non-cash charges added back $1.4M of depreciation and $14.2M of share-based compensation. Working capital and other items added $4.5M. Capital expenditures of $3.6M left free cash flow of $71.2M.
Questions
What was Krystal Biotech's revenue in the second quarter 2026?
Krystal Biotech (KRYS) reported revenue of $119M for the second quarter 2026 (Q2 2026), +24% from a year earlier and +2% from the quarter before.
Was Krystal Biotech profitable in the second quarter 2026?
Operating profit was $58.4M (49.0% of revenue) and net earnings $54.8M.
Source: Krystal Biotech 10-Q on SEC EDGAR.